Batimastat (MMP Inhibitor)

• CAT Number: I001164
• CAS Number: 130370-60-4
• Molecular Formula: C₂₃H₃₁N₃O₄S₂
• Molecular Weight: 477.64
• Purity: ≥95%
• Synonyms: (2S,3R)-N1-hydroxy-3-isobutyl-N4-((S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl)-2-((thiophen-2-ylthio)methyl)succinamide
• Target: MMP
• Solubility: 10 mM in DMSO
• Storage: -20°C
• IC50: 3 nM (MMP-1); 4 nM (MMP-2); 20 nM (MMP-3); 6 nM (MMP-7); 4 nM (MMP-9)
• IUPAC Name: (2S,3R)-N-hydroxy-N'-[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-(thiophen-2-ylsulfanylmethyl)butanediamide
• InChI: InChI=1S/C23H31N3O4S2/c1-15(2)12-17(18(22(28)26-30)14-32-20-10-7-11-31-20)21(27)25-19(23(29)24-3)13-16-8-5-4-6-9-16/h4-11,15,17-19,30H,12-14H2,1-3H3,(H,24,29)(H,25,27)(H,26,28)/t17-,18+,19+/m1/s1
• InChIKey: XFILPEOLDIKJHX-QYZOEREBSA-N
• SMILES: CC(C)CC(C(CSC1=CC=CS1)C(=O)NO)C(=O)NC(CC2=CC=CC=C2)C(=O)NC

Batimastat (Cat No.:I001164) is a highly potent and broad-spectrum inhibitor of matrix metalloproteases (MMPs). It effectively targets various MMPs including MMP-1, MMP-2, MMP-9, MMP-7, and MMP-3 with IC50 values of 3nM, 4nM, 4nM, 6nM, and 20nM, respectively. By inhibiting MMPs, Batimastat prevents the degradation of extracellular matrix components, thus influencing cellular processes such as tissue remodeling, angiogenesis, and metastasis.

Reference

[1]. Chirivi RG, et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer. 1994 Aug 1;58(3):460-4.
[2]. Botos I, et al. Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2749-54.
[3]. Corbel M, et al. Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor batimastat. J Pathol. 2001 Apr;193(4):538-45.
[4]. Giavazzi R, et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res. 1998 Apr;4(4):985-92.
[5]. Low JA, et al. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin Cancer Res. 1996 Jul;2(7):1207-14.
[6]. Macaulay VM, et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res. 1999 Mar;5(3):513-20.